Vertex Pharmaceuticals has unveiled “compelling data” from Phase I and Phase II studies assessing three experimental triple combination regimens for patients with certain forms of cystic fibrosis (CF).
News
GSK to cut 320 jobs amid manufacturing revamp
GlaxoSmithKline is trimming its UK workforce by around 320 under a shake-up of its manufacturing network in the country, in a move designed to boost efficacy and competitiveness.
EU nod for Gedeon’s novel antipsychotic Reagila
European regulators have approved Gedeon Richter’s novel antipsychotic Reagila as a new option for the treatment of patients with schizophrenia.
US nod for Gilead’s pan-genotypic hep C pill
The US Food and Drug Administration has waved through Gilead’s new hepatitis C therapy Vosevi, offering adults with all genotypes of the condition a new treatment option in the form of three medicines in a single pill.
Shire bags rights to bi-specific antibody for haemophilia
Shire has snapped up exclusive worldwide rights from Novimmune for an innovative, bispecific antibody currently in preclinical development for the treatment of patients with haemophilia A and haemophilia A with inhibitors.
Gov’t dishes up £325m for local STP schemes
Fifteen projects embedded in local Sustainability and Transformation Parternship plans across the country are to get a share of a £325 million cash injection from the government to modernise care for patients.
Communications Team of the Year 2017: Why agencies love taking part (…and you would too!)
The PharmaTimes Communications Team of the Year competition is a fantastic opportunity for forward thinking agencies to sharpen their skills and stand out from the crowd.
Teva, Cephalon accused of pay-for-delay deal
European regulators believe that Teva and Cephalon breached antitrust rules with an agreement that effectively delayed the entry of generic competition to the latter’s blockbuster sleep disorder drug modafinil.
US OK’s Puma’s new breast cancer therapy
Puma Biotechnology’s experimental breast cancer therapy Nerlynx has been issued a green light by the US Food and Drug Administration.
UK behind Europe in cancer diagnosis, treatment, survival
The UK is lagging behind Europe in the diagnosis and treatment of cancer, finds a new report compiled by Swedish Institute for Health Economics for the Association of the British Pharmaceutical Industry.
Allergy Therapeutics eyes 15% sales jump
UK group Allergy Therapeutics has announced that its sales for the year are on track to overshoot market expectations at £64.1 million, as its hay fever vaccines continue to gain ground in core European markets.
What it means to be crowned ‘Marketer of the Year’
“Testing capabilities and stimulating professional growth”
Previous winners tell us what it means to be crowned ‘Marketer of the Year’……
“The pharmaceutical industry attracts and retains some of the world’s leading talent. With this in mind, it’s a great honor and privilege to be awarded PharmaTimes New Marketer of the Year 2015.
NHS takes top spot in healthcare system ranking
The UK has been voted number one out of 11 countries in a report ranking international healthcare systems published by the Commonwealth Fund, for the second time running.
US regulators turn away Amgen/UCB’s bone drug Evenity
Amgen and UCB’s application to market bone-boosting drug Evenity as a treatment for postmenopausal women with osteoporosis has hit a setback, having been turned down by US regulators.
Novartis says Cosentyx safe and effective for five years
Novartis has unveiled long-term data indicating that its psoriasis drug Cosentyx is safe and effective for at least five years.
